Review article: visceral hypersensitivity in irritable bowel syndrome: molecular mechanisms and therapeutic agents
- 3 August 2009
- journal article
- review article
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 30 (5) , 423-435
Abstract
Summary: Background Although development of visceral pain is an important defensive mechanism, hypersensitivity results in a significant clinical problem and is likely to be one of the major factors involved in the pathogenesis of abdominal and chest pain in functional bowel disorders (FBDs). Understanding of the molecular mechanisms involved in peripheral sensitization of visceral nociceptors has advanced as a result of the experimental studies, especially in animal models, which have led to knowledge and identification of key mediators and receptors.Aim To provide a comprehensive review focused on the peripheral mechanisms believed to be responsible for sensitization and potential molecular targets for a disorder which is common, distressing and has sub‐optimal treatment options.Methods Literature review using Ovid and Pubmed from 1966.Results There is substantial interest in the development of new drugs for treatment of FBDs in the background of advances in understanding the molecular and physiological mechanisms of visceral hypersensitivity. The potential drug targets include TPRV1, ASICs, voltage‐gated sodium channels, ATP, PAR‐2, cannabinoid, prostaglandin, tachykinin and 5HT3 receptors.Conclusion It is anticipated that with advancing molecular understanding of the basis of visceral hypersensitivity, the next decade will see accelerated development of new molecules for treatment of functional bowel diseases.Keywords
This publication has 103 references indexed in Scilit:
- Increased capsaicin receptor TRPV1-expressing sensory fibres in irritable bowel syndrome and their correlation with abdominal painGut, 2008
- Novel therapeutic approaches in IBSCurrent Opinion in Pharmacology, 2007
- Importance of 5‐hydroxytryptamine receptors on intestinal afferents in the regulation of visceral sensitivityNeurogastroenterology & Motility, 2007
- Characterization of SB-705498, a Potent and Selective Vanilloid Receptor-1 (VR1/TRPV1) Antagonist That Inhibits the Capsaicin-, Acid-, and Heat-Mediated Activation of the ReceptorThe Journal of Pharmacology and Experimental Therapeutics, 2007
- Role for protease activity in visceral pain in irritable bowel syndromeJournal of Clinical Investigation, 2007
- The Mechanosensitivity of Mouse Colon Afferent Fibers and Their Sensitization by Inflammatory Mediators Require Transient Receptor Potential Vanilloid 1 and Acid-Sensing Ion Channel 3The Journal of Neuroscience, 2005
- Visceral HypersensitivityJournal of Clinical Gastroenterology, 2005
- Alosetron relieves pain and improves bowel function compared with mebeverine in female nonconstipated irritable bowel syndrome patientsAlimentary Pharmacology & Therapeutics, 1999
- Impact of irritable bowel syndrome on quality of lifeDigestive Diseases and Sciences, 1996
- Opioid and anti‐opioid peptidesFundamental & Clinical Pharmacology, 1995